Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method

References

• Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016;39:561–575.
   PubMed Web of Science ®Google Scholar
• Shahbaz O, Mahajan S, Lewis JH. Highlights of drug- and herb-induced liver injury in the literature from 2016: how best to translate new information into clinical practice? Exp Opin Drug Metab Toxicol. 2017;13:935–951.
   PubMed Web of Science ®Google Scholar
• Teschke R. Commentary. Drug- and herb-induced liver injury in 2016 with highly appreciated critical comments: related or not, that is the question! Clin Diagn Pathol. 2018;2:1–2.
   Google Scholar
• Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int. 2015;35:1801–1808.
   PubMed Web of Science ®Google Scholar
• Raschi E, De Ponti F. Drug-induced liver injury: towards early prediction and risk stratification. World J Hepatol. 2017;9:30–37.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schulze J, Eickhoff A, et al. Drug induced liver injury: can biomarkers assist RUCAM in causality assessment? Special issue: molecular research on drug induced liver injury. Int J Mol Sci. 2017;18:803.
   Web of Science ®Google Scholar
• Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17:224.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. Review: drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol. 2018;84:1467–1477.
   PubMed Web of Science ®Google Scholar
• Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999;44:731–735.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. Br Med J. 1999;319:154.
   Google Scholar
• Danan G, Bénichou C. Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330.
   PubMed Web of Science ®Google Scholar
• Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs – II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–1336.
   PubMed Web of Science ®Google Scholar
• Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17,14.
   Web of Science ®Google Scholar
• Danan G, Teschke R. Drug-induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch? Drug Saf. 2018;41:735–743.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–489.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Fernández MC, et al. Spanish group for the study of drug-induced liver disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521.
   PubMed Web of Science ®Google Scholar
• Wai CT. Presentation of drug-induced liver injury in Singapore. Singapore Med J. 2006;47:116–120.
   PubMedGoogle Scholar
• Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long term follow-up in a hepatotoxicity registry. Hepatology. 2006;44:1581–1588.
   PubMed Web of Science ®Google Scholar
• García-Cortés M, Lucena MI, Pachkoria K, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27:780–789.
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Dierkhising R, Kremers WK, et al. Single center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105:2396–2404.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Molokhia M, Shen Y, et al. Spanish DILI Registry, EUDRAGENE, DILIN, DILIGEN, and International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141:338–347.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–380.
   PubMed Web of Science ®Google Scholar
• Stammschulte T, Treichel U, Pachl H, et al. Cases of liver failure in association with flupirtine in the German spontaneous reporting system. [cited 2018 Jul 25]. Available from: http://www.akdae.de/Kommission/Organisation/Aufgaben/Publikationen/PDF/Stammschulte2012.pdf
   Google Scholar
• Stephens C, López-Nevot MÁ, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013;8(7):e68111. Erratum: PLoS One 2014; 9(10):e112165.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425.
   PubMed Web of Science ®Google Scholar
• Douros A, Bronder E, Andersohn F, et al. Drug-induced liver injury: results from the hospital-based Berlin case-control surveillance study. Br J Clin Pharmacol. 2014;79:988–999.
   Web of Science ®Google Scholar
• Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, et al. on behalf of the Spanish DILI Registry and the SLatinDILI network. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther. 2015;41:116–125.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Niu M, Chen J, et al. Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. J Gastroenterol Hepatol. 2016;31:1476–1482.
   PubMed Web of Science ®Google Scholar
• Rathi C, Pipaliya N, Patel R, et al. Drug induced liver injury at a tertiary hospital in India: etiology, clinical features and predictors of mortality. Ann Hepatol. 2017;16:442–450.
   PubMed Web of Science ®Google Scholar
• Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016;28:131–142.
   Google Scholar
• Iorga A, Dara L, Kaplowitz N. Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. In: special issue. Molecular research on drug induced liver injury, guest editors R. Teschke and G. Danan. Int J Mol Sci. 2017;18:1018.
   Web of Science ®Google Scholar
• Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 2009;16:3041–3053.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806–815.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. Causality assessment methods in drug-induced liver injury. In: Minjun Chen and Yvonne Will. Series: Methods in Pharmacology and Toxicology, James Kang Y, Casey DC, editors. Drug-induced Liver Toxicity (Chapter 27). Berlin Germany: Springer Protocols, Springer Nature; 2018. p. 555–594. DOI:10.1007/978-1-4939-7677-5_27
   Google Scholar
• Teschke R, Danan G. Drug induced liver injury. In: Radu-Ionita F, Pyrsopoulos NT, Jinga M, et al., editors. New approach of liver diseases: mechanism and management. Springer London Ltd; 2019; in press.
   Google Scholar
• Teschke R, Frenzel C, Wolff A, et al. Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol. 2014;13:248–255.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123–130.
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–455.
   PubMed Web of Science ®Google Scholar
• De Valle MB, Klinteberg AV, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24:1187–1195.
   PubMed Web of Science ®Google Scholar
• Cheetham TC, Lee J, Hunt CM, et al. An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data. Pharmacoepidemiol Drug Saf. 2014;23:601–608.
   PubMed Web of Science ®Google Scholar
• Teschke R, Frenzel C, Schulze J, et al. Herbalife hepatotoxicity: evaluation of cases with positive reexposure tests. World J Hepatol. 2013;5:353–363.
   PubMedGoogle Scholar
• Teschke R, Genthner A, Wolff A, et al. Herbal hepatotoxicity: analysis of cases with initially reported positive reexposure tests. Dig Liv Dis. 2014;46:264–269.
   Web of Science ®Google Scholar
• Teschke R, Eickhoff A, Schwarzenboeck A, et al. Clinical review: herbal hepatotoxicity and the call for systematic data documentation of individual cases. J Liver Clin Res. 2015;2(1):1008. [cited 2018 Jul 25]. Available from: http://www.jscimedcentral.com/Liver/liver-2-1008.pdf
   Google Scholar
• Teschke R, Danan G. Review article: diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf. 2016;39:729–744.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. Drug-induced liver injury: is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13:425–438.
   PubMed Web of Science ®Google Scholar
• Hennes EM, Zeniya M, Czaja AJ, et al. International autoimmune hepatitis group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.
   PubMed Web of Science ®Google Scholar
• Teschke R, Frenzel C. Drug induced liver injury: do we still need a routine liver biopsy for diagnosis today? Ann Hepatol. 2014;13:121–126.
   Web of Science ®Google Scholar
• Teschke R, Schulze J, Eickhoff A, et al. Mysterious Hawaii liver disease case – naproxen overdose as cause rather than OxyELITE Pro? J Liver Clin Res. 2015;22:1013. Available from: http://www.jscimedcentral.com/Liver/liver-2-1013.pdf
   Google Scholar
• Teschke R, Schwarzenboeck A, Frenzel C, et al. The mystery of the Hawaii liver disease cluster in summer 2013: a pragmatic and clinical approach to solve the problem. Ann Hepatol. 2016;15:91–119. Available from: http://www.annalsofhepatology.com.mx/revista/numeros/2016/HP161-12-Mystery%20(web)%20(FF_041215V)_PROTEGIDO%20(1).pdf
   PubMed Web of Science ®Google Scholar
• Teschke R, Eickhoff A. The Honolulu liver disease cluster at the medical center: its mysteries and challenges. Int J Mol Sci. 2016;17(4):476.
   PubMed Web of Science ®Google Scholar
• Teschke R, Eickhoff A. Suspected liver injury and the dilemma of causality. Dig Dis Sci. 2017;62:1095–1098.
   PubMed Web of Science ®Google Scholar
• Willson C. Dietary supplements containing Aegeline and DMAA (1,3-Dimethylamylamine) and their role in liver injury. Int J Med Res Health Sci. 2018;7:10–35. Available from: http://www.ijmrhs.com/archive/ijmrhs-volume-7-issue-7-july-2018.html
   Web of Science ®Google Scholar
• Willson C. An evaluation of case report studies concerning dietary supplements containing Aegeline and DMAA (1,3-Dimethylamylamine). Int J Med Res Health Sci. 2018;7:162–173. [cited 2018 Aug 1]. Available from: https://www.ijmrhs.com/medical-research/an-evaluation-of-case-report-studies-concerning-dietary-supplements-containing-aegeline-and-dmaa-13dimethylamylamine.pdf
   Web of Science ®Google Scholar
• Gibbons RD. OxyELITE Pro and liver disease: statistical assessment of an apparent association. J Statistical Theory Practice. 2018;12. DOI:10.1080/15598608.2017.1305923
   PubMed Web of Science ®Google Scholar
• Teschke R, Wolff A, Eickhoff A, et al. Is obesity rather than the dietary supplement used for weight reduction the cause of liver injury? J Gastroenterol Hepatol Open. 2018;2:152–157.
   Google Scholar
• Roytman MA, Poerzgen P, Navarro V. Botanicals and hepatotoxicity. Clin Pharmacol Ther. 2018;104:458–469.
   PubMed Web of Science ®Google Scholar
• Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11:221–241.
   PubMed Web of Science ®Google Scholar
• Jing J, Teschke R. Traditional Chinese medicine (TCM) and herb induced liver injury: comparison with drug induced liver injury. J Clin Transl Hepatol. 2018;6:1–12.
   PubMed Web of Science ®Google Scholar
• Teschke R, Andrade R. Editorial. Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology. 2015;148:1271–1273.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. Editorial. Prospective Indian study of DILI with confirmed causality using the Roussel Uclaf Causality assessment method (RUCAM): a report of excellence. Ann Hepatol. 2017;16:324–325.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63:590–603.
   PubMed Web of Science ®Google Scholar
• Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008? Expert Opin Drug Metab Toxicol. 2009;5:843–860.
   PubMed Web of Science ®Google Scholar
• Mahady GB, Low Dog T, Barrett ML, et al. United States pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause. 2008;15:628–638.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiol Drug Saf. 2011;20:567–582.
   PubMed Web of Science ®Google Scholar
• Naser B, Schnitker J, Minkin MJ, et al. Hepatotoxicity suspected by black cohosh: no evidence by metaanalysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause. 2011;18:366–375.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schmidt-Taenzer W, Wolff A. USP suspected herbal hepatotoxicity: quality of causality assessment is more important than quantity of counted cases, not vice versa. Pharmacoepidemiol Drug Saf. 2012;21:336–338.
   Web of Science ®Google Scholar
• Teschke R, Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf. 2012;35:1091–1097.
   PubMed Web of Science ®Google Scholar
• Heidemann LA, Navarro VJ, Ahmad J, et al. Severe acute hepatocellular injury attributed to OxyELITE Pro: a case series. Dig Dis Sci. 2016;61:2741–2748.
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914–928.
   PubMed Web of Science ®Google Scholar
• Shi Q, Hong H, Senior J, et al. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol. 2014;4:225–234.
   Google Scholar
• Senior JR. New biomarker for drug induced liver injury: are they really better? what do they diagnose? Liver Int. 2014;34:325–327.
   PubMed Web of Science ®Google Scholar
• Lewis JH. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol. 2015;13:2173–89.e8.
   PubMed Web of Science ®Google Scholar
• McGill MR, Jaeschke H. MicroRNAs as signaling mediators and biomarkers of drug- and chemical-induced liver injury. J Clin Med. 2015;4:1063–1078.
   PubMed Web of Science ®Google Scholar
• Zheng J, Ji C, Lu X, et al. Integrated expression profiles of mRNA and microRNA in the liver of Fructus Meliae Toosendan water extract injured mice. Front Pharmacol. 2015;6:236.
   PubMed Web of Science ®Google Scholar
• Enache LS, Enache EL, Ramière C, et al. Circulating RNA molecules as biomarkers in liver disease. Int J Mol Sci. 2014;15:17644–17666.
   PubMed Web of Science ®Google Scholar
• Li LM, Wang D, Zen K. MicroRNAs in drug-induced liver injury. Clin Transl Hepatol. 2014;2:162–169.
   PubMedGoogle Scholar
• Yang X, Salminen WF, Schnackenberg LK. Current and emerging biomarkers of hepatotoxicity. Curr Biomarker Find. 2012;20:43–55.
   Google Scholar
• Lewis PJS, Dear J, Platt V, et al. Circulating RNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54:1767–1776.
   PubMed Web of Science ®Google Scholar
• Thulin P, Nordahl G, Gry M, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int. 2014;34:367–378.
   PubMed Web of Science ®Google Scholar
• Su YW, Chen X, Jiang ZZ, et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS One. 2012;7(5):e37395.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. Editorial. Drug-induced liver injury, mortality, and liver transplantation: is it reasonable to use a global introspection causality assessment? AME Med J. 2017;2:144.
   Google Scholar
• Teschke R, Eickhoff A, Wolff A, et al. Liver injury from herbs and “dietary supplements”: highlights of a literature review from 2015 to 2017. Curr Pharmacol Rep. 2018;4:120–131.
   Google Scholar
• Teschke R, Larrey D, Melchart D, et al. Traditional Chinese Medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines. 2016;3:18.
   Google Scholar